GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Subscribe To Our Newsletter & Stay Updated
